Director, Global Value, Access & Pricing – CRC

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Value, Access & Pricing – CRC is responsible for developing and driving global access and pricing strategies for Revolution Medicines’ CRC assets to enable timely, sustainable patient access across key markets. This role ensures payer and HTA requirements are embedded into clinical development, indication sequencing, and launch planning from early-stage development through commercialization. The Director serves as the global access lead on cross-functional asset teams and partners closely with HEOR, Clinical Development, Regulatory, Commercial, Finance, and Regional Market Access to align global strategy with regional execution. Key responsibilities: Lead development of global pricing and market access strategies for CRC assets, including launch sequencing, reference pricing considerations, and price corridor management across priority markets. Identify payer-relevant evidence requirements and partner with HEOR to align evidence generation plans with global reimbursement needs. Assess CRC competitive dynamics, including line-of-therapy positioning, biomarker-driven access considerations, and combination therapy reimbursement implications. Guide EU Joint Clinical Assessment (JCA) strategy and submission preparation in collaboration with regional Market Access and HEOR teams. Build and maintain strong relationships with Clinical, Commercial, Regulatory, HEOR, and Medical Affairs functions. Provide strategic direction to regional teams on pricing implementation, reimbursement risk mitigation, and negotiation readiness. Contribute to Global Market Access capability-building efforts to strengthen organizational knowledge and effectiveness. Provide strategic market access input into clinical development programs to optimize endpoints, comparators, and evidence packages for payer and HTA success. Monitor, analyze, and communicate global access and pricing trends, competitor activities, and policy changes. Contribute access and pricing assessments to lifecycle planning and business development evaluations. Required Skills, Experience and Education: Bachelor’s degree required; advanced degree Ph.D., PharmD, MD, or MSc in Health Economics, Public Health, Health Policy, or a related field preferred. 10+ years of relevant experience in market access and pricing, ideally with global leadership exposure. Strong experience in pricing & reimbursement of oncology products. Deep understanding of global payer systems and HTA processes, including AMNOG, Chuikyo, NICE, and other EU frameworks. Experience designing and implementing global pricing strategy, including value-based pricing, launch sequencing, and reference pricing mitigation. Experience with pricing regulations, early pricing analysis, and pricing negotiations (country level experience preferred). Demonstrated ability to support clinical development to satisfy payer/HTA evidence needs. Experience engaging HTA and payer organizations in early advice to inform development and trial strategies. Preferred Skills: Strategic and analytical thinking with strong problem-solving skills. Excellent communication, leadership, and cross-functional collaboration abilities. Proven track record influencing decisions an